Core Viewpoint - Ocugen, Inc. has completed enrollment for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP), with topline data expected in Q1 2027, which may support a Biologics License Application (BLA) filing and potential approval in 2027 [1][5] Company Developments - The liMeliGhT clinical trial enrolled 140 patients, randomized into treatment and control groups, targeting early- to late-stage RP patients, including pediatric cases [2][3] - The primary endpoint of the trial is the 12-month change in visual function, assessed by a proprietary test called LDNA [2] - Ocugen is on track to file a rolling BLA in Q3 2026, following positive long-term data from a previous Phase 1/2 study showing approximately 2-line gains in visual acuity [4][5] Clinical Trial Insights - The Phase 3 trial is notable for its broad representation of gene mutations associated with RP, supporting a gene-agnostic therapeutic approach [3] - Positive long-term data from the Phase 1/2 study indicated that 88% of evaluable treated subjects showed improvement or preservation of visual function over three years [6] Treatment Landscape - Currently, there are no approved treatments that effectively address the needs of the approximately 98% of RP patients who are not candidates for existing gene therapies [4][9] - OCU400 aims to reset dysfunctional gene networks in retinal cells, potentially improving vision for patients with RP [7][9] Industry Context - RP is a group of rare genetic disorders leading to vision loss, associated with mutations in over 100 genes, highlighting the need for innovative, gene-agnostic therapies [8][9] - The development of novel therapeutic approaches targeting broader RP disease mechanisms offers hope for patients with multiple and unknown genetic mutations [9]

Financial Data and Key Metrics Changes - The company's cash, cash equivalents, and restricted cash totaled $32.9 million as of September 30, 2025, down from $58.8 million as of December 31, 2024 [13] - Total operating expenses for the three months ended September 30, 2025, were $19.4 million, compared to $14.4 million for the same period in 2024 [14] Business Line Data and Key Metrics Changes - The OCU400 phase three LI M EL IGHT clinical trial is on track for BLA and MAA submissions in 2026, addressing multiple genetic mutations with a single therapeutic approach [7] - OCU410 is designed to address multiple pathways implicated in dry age-related macular degeneration, showing a 23% reduction in lesion growth at 12 months [12] Market Data and Key Metrics Changes - Approximately 300,000 people in the U.S. and Europe combined live with Retinitis Pigmentosa (RP), with OCU400 targeting the remaining 98-99% of RP patients [7][8] - There are an estimated 7,000 individuals in South Korea with RP, representing about 7% of the U.S. market [9] Company Strategy and Development Direction - The company aims to file three BLAs in the next three years, with a focus on addressing unmet medical needs for patients facing vision loss [5] - Ocugen is pursuing regional partnerships to maximize patient reach while generating returns for shareholders, including an exclusive licensing agreement with Kwang Dong Pharmaceutical for OCU400 in South Korea [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of clinical trials and the potential for OCU400 to provide a therapeutic option for a large patient population [8] - The company anticipates commercialization of OCU400 in 2027, with brand planning and marketing initiatives already underway [8] Other Important Information - The company closed a registered direct offering with Janus Henderson in August, raising approximately $20 million to extend its runway through the second quarter of 2026 [6] - The interim data from the ongoing phase two three study for OCU14ST is expected mid-2026, further advancing the goal of bringing the treatment to patients [11] Q&A Session Summary Question: Timing of BLA completion for OCU400 - Management indicated that resources are ready to turn around pivotal data to the FDA in weeks [15] Question: Manufacturing readiness for commercial production - The company confirmed that process validation runs are on target and materials for registration can be commercialized [16] Question: Endpoints for OCU410ST interim readout - The primary endpoint is lesion growth compared to untreated controls, with visual acuity as a secondary endpoint [17] Question: Statistical design of the LIMELIGHT study for OCU400 - The study includes a control arm and has a planned enrollment of 150 subjects, with a 97% power for the study [19] Question: Enrollment progress for OCU410ST - Enrollment is on track with no geographical restrictions, covering a pediatric population [24] Question: Commercial strategy for OCU400 - The company is targeting a broad indication for RP, including various mutations to maximize treatment potential [25] Question: Regulatory path for OCU400 in South Korea - Approval in South Korea is expected to follow FDA approval without the need for additional clinical trials [29] Question: Manufacturing capacity for larger indications - The company has a facility in Pennsylvania and plans to produce all U.S. supply from this site by 2027 [30]